Dexcom CGM starred in the 81st Scientific Sessions of the American Diabetes Association

0


SAN DIEGO–(BUSINESS WIRE) –DexCom, Inc. (NASDAQ: DXCM), the world’s leading provider of real-time continuous glucose monitoring (CGM) for people with diabetes, today announced research and data presentations to host the 81st scientific session of the American Diabetes Association (ADA) virtual conference in June will be 25.-29. 2021.

“It is noteworthy that there is increasing research and data from year to year that continues to show that CGM is central to optimal diabetes management, regardless of how a person administers insulin,” said Jake Leach, chief technology officer Officer at Dexcom. “In addition, we are now seeing increasing evidence of the benefits of CGM for broader populations, including those with type 2 diabetes who do not use insulin, inpatient care, and even for general health and wellbeing.”

Key posters and research presented at ADA include:

Dexcom CGM driven results:

  • Poster 69-LB, “Nonadjunctive Continuous Glucose Monitoring to Control Hypoglycemia (COACH)” (Stayce Beck)

  • Poster 76-LB, “Baseline A1C Values ​​and Magnitude of A1C Reductions during Nonadjunctive Continuous Glucose Monitoring Use in the COACH Study” (Stayce Beck)

Dexcom Feature Engagement and Performance:

  • Poster 601-P, “Time-in-range is more affected by high-threshold warning messages than the frequency of screen views for users of a real-time CGM system” (Robert Dowd)

  • Poster 622-P, “Frequent engagement with retrospective real-time CGM data is associated with improved glycemic control” (Joost van der Linden)

  • Poster 70-LB, “Continuous data exchange for glucose monitoring in older adults with type 1 diabetes and their caregivers” (Nancy A. Allen)

Type 2 Diabetes Health Outcomes, Economic Outcomes, and Market Access:

  • Presentation: Breaking through the glass ceiling with new clinical approaches for rtCGM. Moderated by Guillermo Umpierrez, MD on Saturday, June 26, 2021, 12:30 PM – 1:45 PM ET. Speakers include: Richard Bergenstal, MD; Nicole Ehrhardt, MD; Thomas Martens, MD

  • Presentation: Clinical Evidence and Practical Applications to Implement Real-Time Continuous Glucose Monitoring (rt-CGM) in Adults with Type 2 Diabetes (T2D). Moderated by Christine Pospisil RD, LD, CDCES, Monday, June 28, 2021, 1:00 p.m. ET. Speakers include: Thomas Blevins, MD, ENCU, FACE, FNLA, Thomas Grace, MD, Kristyn Milburn, MSN, NP-C, BC-ADM, CDCES.

  • Poster 66-LB: “Continuous real-time glucose monitor (RTCGM) in connection with reduced medical costs in diabetes in patients with type 2 diabetes (T2D)” (Greg Norman)

  • Poster 77-LB, “A Retrospective Analysis of the Association between HbA1c and Continuous Glucose Monitor Use in US Patients with Type 2 Diabetes” (Greg Norman)

  • Poster 597-P, “Long-Term A1C Results With and Without Intermittent CGM Use in Adults with T2D Participating in the Onduo Program” (Jennifer E. Layne)

  • Poster 600-P, “Real-time CGM Coverage Eligibility Should Include Patients With Type 2 Diabetes Treated With Less Intensive Therapy” (Thomas Grace)

Patient monitoring:

  • Presentation: Breaking through the glass ceiling with new clinical approaches for rtCGM. Moderated by Guillermo Umpierrez, MD on Saturday, June 26, 2021, 12:30 PM – 1:45 PM ET. Speakers include: Richard Bergenstal, MD; Nicole Ehrhardt, MD; Thomas Martens, MD

  • Poster 613-P, “Performance evaluation of continuous glucose monitoring with Dexcom G6 and capillary blood sugar after hospital discharge in patients with diabetes” (Rodolfo J. Galindo)

  • Poster 619-P, “Comparison of Dexcom G6 Continuous Glucose Monitoring and Point-of-Care Blood Glucose Tests in Hospital Patients with Diabetes” (Georgia M. Davis)

Health and Wellness:

  • Oral 154-OR: “People Who Sleep More Hours Have Lower Mean Blood Glucose Levels: Analysis of Continuous Glucose Monitoring and Fitbit Data in a Free Living Population Without Diabetes” (Margaret Crawford) (Sunday, June 27, 2021 from 9:45 am Until 10:00 a.m.)

In addition, there are more than a dozen ADA posters and presentations highlighting health outcomes and quality of life improvements from automated insulin delivery systems built into Dexcom CGM.

For more information on the American Diabetes Association’s 81st Scientific Sessions and to attend the conference virtually, please visit professional.diabetes.org/scientific-sessions.

About DexCom, Inc.

Headquartered in San Diego, California, DexCom, Inc. is committed to helping people better manage their diabetes by developing and marketing Continuous Glucose Monitoring (CGM) products and instruments for adult and pediatric patients. With exceptional performance, patient comfort, and lifestyle flexibility at the heart of its technology, users have consistently rated DexCom for the highest levels of customer satisfaction and loyalty. For more information, visit www.dexcom.com.



Source link

Leave A Reply

Your email address will not be published.